GlassScriptPhysician profile
Matthew T Porter
NPI 1477791606
$1,114.47
in general payments reported to CMS, 2019-2025
16 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $36.59 · 2021: $338 · 2022: $181 · 2023: $147 · 2024: $145 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.54 | 2019-2025 | |
| Gilead Sciences, INC. | $199.84 | 2019-2023 | |
| Lilly USA, LLC | $162.28 | 2019-2025 | |
| Pfizer INC. | $87.19 | 2022-2025 | |
| Braeburn INC. | $81.82 | 2023-2025 | Brixadi |
| Indivior INC. | $41.96 | 2021-2024 | Sublocade |
| Amgen INC. | $39.95 | 2022-2023 | Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.94 | 2022-2025 | Caplyta |
| Abbott Laboratories | $22.27 | 2024 | Freestyle Libre |
| Novo Nordisk INC | $21.83 | 2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $18.42 | 2024 | Abilify Maintena, Rexulti |
| Glaxosmithkline, LLC. | $18.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.58 | 2019 | |
| Dexcom, INC. | $14.90 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $14.37 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $9.45 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.